Search Result

Results for "

TRPC5

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (4) Autophagy (7) Ferroptosis (7) HCV (2) HCV Protease (2) Histamine Receptor (2) Isotope-Labeled Compounds (2) PPAR (7) Small Interfering RNA (siRNA) (1) TRP Channel (26)
By Research Areas:	Cancer (12) Cardiovascular Disease (1) Endocrinology (2) Inflammation/Immunology (10) Metabolic Disease (11) Neurological Disease (12)

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-142030

TRPC5 modulator-1

TRP Channel Neurological Disease

TRPC5 modulator-1 (Compound 9) is a TRPC5 modulator with an IC₅₀ of <1 nM for the research of neuropsychiatry disorders .

TRPC5 modulator-1	TRP Channel	Neurological Disease
TRPC5 modulator-1 (Compound 9) is a *TRPC5* modulator with an IC₅₀ of <1 nM for the research of neuropsychiatry disorders .

HY-RS15108

TRPC5 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TRPC5 Human Pre-designed siRNA Set A contains three designed siRNAs for TRPC5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TRPC5 Human Pre-designed siRNA Set A TRPC5 Human Pre-designed siRNA Set A

HY-145150

TRPC5-IN-1	TRP Channel	Metabolic Disease
TRPC5-IN-1 (Compound 6j) is a selective *TRPC5* inhibitor with 50.5 % Inhibition for TRPC5 at 3 μM. TRPC5-IN-1 can be used for the research of chronic kidney disease (CKD) .

HY-144429

TRPC5-IN-4	TRP Channel	Metabolic Disease
TRPC5-IN-4 is potent and safe *TRPC* inhibitor with IC₅₀ value of 14.07 nM and 65 nM for *TRPC5* and *TRPC4, respectively. TRPC5-IN-4 shows no damage on the cellular component of liver and kidney. TRPC5*-IN-4 can be used for the research of chronic kidney disease (CKD) .

HY-144205

TRPC5-IN-2

TRP Channel Others

TRPC5-IN-2 is a potent TRPC5 inhibitor (WO2019055966A2, Compound IO) .
HY-144208

TRPC5-IN-3

TRP Channel Others

TRPC5-IN-3 is a potent TRPC5 inhibitor with IC₅₀ of 10.75 nM (WO2022001767A1, L001) .

TRPC5-IN-2	TRP Channel	Others
TRPC5-IN-2 is a potent *TRPC5* inhibitor (WO2019055966A2, Compound IO) .

TRPC5-IN-3	TRP Channel	Others
TRPC5-IN-3 is a potent *TRPC5* inhibitor with IC₅₀ of 10.75 nM (WO2022001767A1, L001) .

HY-132813

Evifacotrep	TRP Channel	Neurological Disease
Evifacotrep, a short transient receptor potential channel 5 and 4 (TRPC5/TRPC4) antagonist (WO2020061162, compound 100), can be used for the research of neurological diseases. Evifacotrep targets to *TRPC5/TRPC4* with IC₅₀s ≤50 nM .

HY-133168

Englerin A	TRP Channel	Cancer
Englerin A is a potent and selective activator of *TRPC4* and *TRPC5* channels, with EC₅₀s of 11.2 and 7.6 nM, respectively. Englerin A can induce renal carcinoma cells death by elevated Ca ²⁺ influx and Ca ²⁺ cell overload .

HY-128561

AM12

TRP Channel Cardiovascular Disease

AM12 inhibits Lanthanide-evoked TRPC5 activity with an IC₅₀ of 0.28 μM .

AM12	TRP Channel	Cardiovascular Disease
AM12 inhibits Lanthanide-evoked *TRPC5* activity with an IC₅₀ of 0.28 μM .

HY-112302

HC-070 3 Publications Verification	TRP Channel	Neurological Disease
HC-070 is an antagonist of *TRPC4/TRPC5, with IC₅₀*s of 9.3 nM and 46 nM for hTRPC5 and hTRPC4 in cells, respectively.

HY-128205

BTD

TRP Channel Neurological Disease

BTD is a selective transient receptor potential canonical 5 (TRPC5) activator. BTD can be used for the research of neurological disease .

BTD	TRP Channel	Neurological Disease
BTD is a selective transient receptor potential canonical 5 *(TRPC5)* activator. BTD can be used for the research of neurological disease .

HY-12949

ML204 4 Publications Verification	TRP Channel	Neurological Disease
ML204 is a potent, selective *TRPC4/TRPC5* channel inhibitor, with at least 19-fold selectivity against TRPC6 and no appreciable effect on all other TRP channels, nor on voltage-gated sodium, potassium, or Ca ²⁺ channels .

HY-12949A

ML204 hydrochloride 4 Publications Verification	TRP Channel	Neurological Disease
ML204 hydrochloride is a novel, potent, selective *TRPC4/TRPC5* channel inhibitor, with at least 19-fold selectivity against TRPC6 and no appreciable effect on all other TRP channels, nor on voltage-gated sodium, potassium, or Ca ²⁺ channels .

HY-162090

TRPC antagonist 1	TRP Channel	Cancer
TRPC antagonist 1 (compound 15g) is a potent TRP channel (TRPC) antagonist with IC₅₀s of 2.4 μM, 12.2 μM, 7.6 μM, 2.9 μM, and 3.4 μM for TRPC3, TRPC4, TRPC5, TPRC6, and TRPC7, respectively. TRPC antagonist 1 displays noteworthy anti-glioblastoma efficacy in vitro against U87 cell lines .

HY-30234A

Clemizole hydrochloride	Histamine Receptor TRP Channel HCV Protease HCV	Inflammation/Immunology Endocrinology Cancer
Clemizole hydrochloride is an H1 histamine receptor antagonist, is found to substantially inhibit HCV replication. Clemizole hydrochloride is an inhibitor of TRPC5 channel. The IC₅₀ of Clemizole hydrochloride for RNA binding by NS4B is 24 nM, whereas its EC₅₀ for viral replication is 8 µM.

HY-30234

Clemizole	Histamine Receptor TRP Channel HCV Protease HCV	Inflammation/Immunology Endocrinology Cancer
Clemizole is an H1 histamine receptor antagonist, is found to substantially inhibit HCV replication. Clemizole is an inhibitor of TRPC5 channel. The IC₅₀ of Clemizole for RNA binding by NS4B is 24±1 nM, whereas its EC₅₀ for viral replication is 8 µM.

HY-17386

Rosiglitazone Maximum Cited Publications 86 Publications Verification BRL 49653	PPAR TRP Channel Autophagy Ferroptosis Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC₅₀: 60 nM, K_d: 40 nM). Rosiglitazone is an TRPC5 activator (EC₅₀: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer .

HY-17386A

Rosiglitazone hydrochloride Maximum Cited Publications 86 Publications Verification BRL 49653 hydrochloride	PPAR TRP Channel Autophagy Ferroptosis Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Rosiglitazone (BRL 49653) hydrochloride is an orally active selective PPARγ agonist (EC₅₀: 60 nM, K_d: 40 nM). Rosiglitazone hydrochloride is a *TRPC5* activator (EC₅₀: 30 μM) and TRPM3 inhibitor. Rosiglitazone hydrochloride can be used in the research of obesity and diabetes, senescence, ovarian cancer .

HY-17386B

Rosiglitazone potassium BRL 49653 potassium	PPAR TRP Channel Autophagy Apoptosis Ferroptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Rosiglitazone (BRL 49653) potassium is an orally active selective PPARγ agonist (EC₅₀: 60 nM, K_d: 40 nM). Rosiglitazone potassium is a *TRPC5* activator (EC₅₀: 30 μM) and TRPM3 inhibitor. Rosiglitazone potassium can be used in the research of obesity and diabetes, senescence, ovarian cancer .

HY-101507

Pico145 5+ Cited Publications HC-608	TRP Channel	Cancer
Pico145 (HC-608) is a remarkable inhibitor of *TRPC1/4/5* channels, inhibits (−)-englerin A-activated TRPC4/TRPC5 channels, with IC₅₀s of 0.349 and 1.3 nM in cells, and shows no effect on TRPC3, TRPC6, TRPV1, TRPV4, TRPA1, TRPM2, TRPM8 .

HY-122051

AC1903 1 Publications Verification	TRP Channel	Metabolic Disease
AC1903 is a specific and selective inhibitor of *TRPC5* and has podocyte-protective properties. AC1903 does no effects on TRPC4 or TRPC6 currents and shows no off-target effects in kinase profiling assays. AC1903 suppresses severe proteinuria and prevents podocyte loss in focal segmental glomerulosclerosis (FSGS) rat model .

HY-17386S1

Rosiglitazone-d4 BRL 49653-d₄	TRP Channel Autophagy PPAR Ferroptosis Apoptosis Isotope-Labeled Compounds	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Rosiglitazone-d₄ is deuterated labeled Rosiglitazone (HY-17386). Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC₅₀: 60 nM, K_d: 40 nM). Rosiglitazone is an TRPC5 activator (EC₅₀: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer .

HY-14600

Rosiglitazone maleate Maximum Cited Publications 86 Publications Verification BRL 49653C	PPAR TRP Channel Autophagy Ferroptosis	Metabolic Disease Inflammation/Immunology Cancer
Rosiglitazone maleate (BRL 49653C) is a potent and selective activator of PPARγ, with EC₅₀s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively, and a K_d of appr 40 nM for PPARγ; Rosiglitazone maleate is also an modulator of TRP channels, inhibits TRP melastatin 2 (TRPM2), TRPM3 and activates TRP canonical 5 (TRPC5).

HY-17386S

Rosiglitazone-d3	Isotope-Labeled Compounds PPAR TRP Channel Autophagy Ferroptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Rosiglitazone-d₃ is the deuterium labeled Rosiglitazone. Rosiglitazone (BRL 49653) is a selective, orally active PPARγ agonist with EC50s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively. Rosiglitazone binds to PPARγ with a Kd of approximately 40 nM. Rosiglitazone is also an activator of TRPC5 (EC50=~30 μM) and an inhibitor of TRPM3[1][2][3][4].

HY-133012

GFB-8438	TRP Channel	Neurological Disease
GFB-8438 is a potent and subtype selective *TRPC5* inhibitor, with IC₅₀s of 0.18 and 0.29 μM of hTRPC5 and hTRPC4, respectively. GFB-8438 shows excellent selectivity against TRPC6, other TRP family members, NaV 1.5, as well as limited activity against the hERG channel. GFB-8438 protects mouse podocytes from injury induced by protamine sulfate model .

HY-14600R

Rosiglitazone maleate (Standard) BRL 49653C (Standard)	PPAR TRP Channel Autophagy Ferroptosis	Metabolic Disease Inflammation/Immunology Cancer
Rosiglitazone (maleate) (Standard) is the analytical standard of Rosiglitazone (maleate). This product is intended for research and analytical applications. Rosiglitazone maleate (BRL 49653C) is a potent and selective activator of PPARγ, with EC₅₀s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively, and a K_d of appr 40 nM for PPARγ; Rosiglitazone maleate is also an modulator of TRP channels, inhibits TRP melastatin 2 (TRPM2), TRPM3 and activates TRP canonical 5 (TRPC5).

HY-146155

TRPC4/5-IN-1	TRP Channel	Metabolic Disease Inflammation/Immunology
TRPC4/5-IN-1 is a potent TRP channel 4/5 (TRPC4/5) inhibitor with IC₅₀s of 2.06 μM and 0.54 μM, respectively. TRPC4/5-IN-1 can be used for proteinuric kidney diseases and skin inflammatory diseases research .

Englerin A	other families Classification of Application Fields Terpenoids Sesquiterpenes Source classification Plants Disease Research Fields Cancer	TRP Channel
Englerin A is a potent and selective activator of *TRPC4* and *TRPC5* channels, with EC₅₀s of 11.2 and 7.6 nM, respectively. Englerin A can induce renal carcinoma cells death by elevated Ca ²⁺ influx and Ca ²⁺ cell overload .

Cat. No.	Compare	Product Name	Species	Source

HY-P701832

	TRPC5 Protein, Human (HEK293, His, MBP, FLAG) TRPC5; Short transient receptor potential channel 5; TRPC5; Transient receptor protein 5; TRP-5; hTRP-5; hTRP5	Human	HEK293
	The TRPC5 protein is hypothesized to be a receptor-activated, nonselective calcium-permeable cation channel, possibly activated by phosphatidylinositol second messengers via receptor tyrosine kinases or G-protein-coupled receptors. Although TRPC5 is thought to have calcium-selective properties, it may also respond to depletion of intracellular calcium stores. TRPC5 Protein, Human (HEK293, His, MBP, FLAG) is the recombinant human-derived TRPC5 protein, expressed by HEK293 , with N-MBP, C-Flag, N-8*His labeled tag. The total length of TRPC5 Protein, Human (HEK293, His, MBP, FLAG) is 972 a.a., .


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Rosiglitazone-d4
Rosiglitazone-d₄ is deuterated labeled Rosiglitazone (HY-17386). Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC₅₀: 60 nM, K_d: 40 nM). Rosiglitazone is an TRPC5 activator (EC₅₀: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer .

Rosiglitazone-d3
Rosiglitazone-d₃ is the deuterium labeled Rosiglitazone. Rosiglitazone (BRL 49653) is a selective, orally active PPARγ agonist with EC50s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively. Rosiglitazone binds to PPARγ with a Kd of approximately 40 nM. Rosiglitazone is also an activator of TRPC5 (EC50=~30 μM) and an inhibitor of TRPM3[1][2][3][4].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks